3 Oversold Health Care Stocks to Watch in Q4

MoonLake Immunotherapeutics (MLTX), CorVel Corp (CRVL), and Harmony Biosciences Holdings Inc (HRMY) are major oversold players in the health care sector with RSI values near or below 30. MLTX's stock fell 86% over the past month, while CRVL's stock fell 14%. HRMY's stock fell 24% over the past month. All three stocks have the potential to rebound in Q4.

MoonLake Immunotherapeutics (MLTX), CorVel Corp (CRVL), and Harmony Biosciences Holdings Inc (HRMY) are major oversold players in the healthcare sector, with Relative Strength Index (RSI) values near or below 30. These stocks, which have experienced significant declines over the past month, present an opportunity for investors looking to capitalize on potential rebounds in the fourth quarter (Q4).

MoonLake Immunotherapeutics (MLTX) reported week-16 results from its Phase 3 VELA-1 and VELA-2 trials, which used HiSCR75—a 75% reduction in abscess and inflammatory nodule count with no increase in abscesses or draining tunnels—as the primary endpoint. Despite the positive results, the company's stock fell around 86% over the past month and has a 52-week low of $5.95. However, MLTX's stock price action shows a 13% jump to close at $8.43 on Friday, indicating a potential rebound Top 3 Health Care Stocks That Are Preparing To Pump In Q4^[1].

CorVel Corp (CRVL) saw its stock fall around 14% over the past month and has a 52-week low of $72.15. On September 12, CorVel's CFO, Brandon T. O’Brien, stepped down. The stock entered oversold territory with an RSI reading of 26.2, suggesting that the recent heavy selling may be nearing exhaustion CorVel Enters Oversold Territory (CRVL)^[2]. CRVL's stock rose 0.6% to close at $73.83 on Friday, indicating a potential uptick in investor sentiment.

Harmony Biosciences Holdings Inc (HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS). The company's stock fell around 24% over the past month and has a 52-week low of $26.26. HRMY's stock gained 2% to close at $27.28 on Friday, signaling a potential breakout Top 3 Health Care Stocks That Are Preparing To Pump In Q4^[1].

While these stocks are currently oversold, investors should remain cautious and conduct thorough due diligence before making any investment decisions. The healthcare sector is known for its volatility, and these stocks' past performance does not guarantee future results.